Sandbox 124: Difference between revisions
No edit summary |
No edit summary |
||
| Line 56: | Line 56: | ||
<scene name='37/372724/Ceftobiprole/1'>ceftobiprole</scene> and | <scene name='37/372724/Ceftobiprole/1'>ceftobiprole</scene> and | ||
ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to | ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to | ||
inhibit PBP2a because additional chemical groups at the <scene name='37/372724/ | inhibit PBP2a because additional chemical groups at the <scene name='37/372724/Ceftobiprole/5'>R2</scene> | ||
position of the cephalosporin backbone are able to interact with additional amino acid | position of the cephalosporin backbone are able to interact with additional amino acid | ||
residues in PBP2a; specifically <scene name='37/372724/Met641_and_tyr446_labeled/1'>Tyr446 and Met641</scene>. | residues in PBP2a; specifically <scene name='37/372724/Met641_and_tyr446_labeled/1'>Tyr446 and Met641</scene>. | ||
As a result of its tighter binding to PBP2a, ceftobiprole | As a result of its tighter binding to PBP2a, ceftobiprole | ||
is able to more efficiently <scene name='37/372724/Rb6_interactions/1'>react with the serine active site</scene> residue and therefore inhibit the activity of PBP2a. | is able to more efficiently <scene name='37/372724/Rb6_interactions/1'>react with the serine active site</scene> residue and therefore inhibit the activity of PBP2a. | ||